Activity of lecithin-cholesterol-acyl transferase (LCAT) was distinctly decreased in chronic impairments of liver tissue, especially under conditions of liver cirrhosis and hepatocellular cancer. After treatment with "essentiale forte" the enzymatic activity was elevated only in the patients with chronic hepatitis. The LCAT activity correlated with content of albumins, gamma-globulins and the data of thymol test. Estimation of the LCAT activity might serve as a diagnostic test in chronic liver tissue diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure.
Gastro Hep Adv
October 2024
Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Victoria, Australia.
Background And Aims: Acute-on-chronic liver failure (ACLF) has a 22%-74% 28-day mortality rate and 30%-40% 30-day readmission rate. We investigated the acceptability and feasibility of a multimodal community intervention for ACLF.
Methods: A single-arm nonrandomized pilot study of consecutive participants with ACLF was conducted in a tertiary health service.
Plasma Circulating Metabolites Associated With Steatotic Liver Disease and Liver Enzymes: A Multiplatform Population-Based Study.
Gastro Hep Adv
September 2024
Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Background And Aims: Steatotic liver disease (SLD) is the most common chronic liver disease strongly associated with metabolic dysfunction, but its pathogenesis remains incompletely understood. Exploring plasma circulating metabolites may help in elucidating underlying mechanisms and identifying new biomarkers for SLD.
Methods: We examined cross-sectionally the association between plasma metabolites and SLD as well as liver enzymes using data from 4 population-based cohort studies (Rotterdam study, Avon Longitudinal Study of Parents and Children, The Insulin Resistance Atherosclerosis Family Study, and Study of Latinos).
Exploring the links between gallstone disease, non-alcoholic fatty liver disease, and kidney stones: A path to comprehensive prevention.
World J Gastroenterol
January 2025
Université de Bourgogne, Institut Agro-INRAe, Dijon 21000, France.
The recent study exploring the bidirectional associations between gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease highlights a critical concern in chronic disease management. Given the rising global prevalence of these conditions, understanding their interconnections is essential. The study emphasizes the importance of shared risk factors, such as obesity, type 2 diabetes, dyslipidemia, and oxidative stress, and calls for multidisciplinary screening strategies.
View Article and Find Full Text PDFDapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis.
Diabetol Int
January 2025
Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, 13 Sur 2901 Colonia Volcanes, 72420 Puebla, Puebla México.
Aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to reduce visceral (VAT) and subcutaneous (SAT) adipose tissue. Although many systematic reviews have examined SGLT2i's effect on VAT and SAT, a focus analysis of dapagliflozin, one of the more commonly prescribe SGLT2i, has yet to been done. This study aims to determine the effect of dapagliflozin on reducing VAT and SAT in patients with chronic disease.
View Article and Find Full Text PDFMulti-target regulatory effects of rhaponticin in a rat model of hepatic fibrosis revealed by non-targeted metabolomics.
Front Pharmacol
January 2025
School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Introduction: Hepatic fibrosis (HF), a progressive chronic liver disease, is a serious threat to global public health. The lack of preventive and therapeutic strategies has created an urgent need for effective anti-fibrosis agents. There is growing evidence that natural products might provide safe and effective interventions for HF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!